These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 38003)

  • 21. Mechanism of action of Escherichia coli phosphoribosylaminoimidazolesuccinocarboxamide synthetase.
    Nelson SW; Binkowski DJ; Honzatko RB; Fromm HJ
    Biochemistry; 2005 Jan; 44(2):766-74. PubMed ID: 15641804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.
    Kensler TW; Reck LJ; Cooney DA
    Cancer Res; 1981 Mar; 41(3):905-9. PubMed ID: 7459876
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-term association of N-(phosphonacetyl)-L-aspartate with bone.
    Ardalan B; Kensler TW; Jayaram HN; Morrison W; Choie DD; Chadwick M; Liss R; Cooney DA
    Cancer Res; 1981 Jan; 41(1):150-6. PubMed ID: 7448755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and bioactivity of novel inhibitors of E. coli aspartate transcarbamoylase.
    Eldo J; Heng S; Kantrowitz ER
    Bioorg Med Chem Lett; 2007 Apr; 17(7):2086-90. PubMed ID: 17336518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
    Moyer JD; Handschumacher RE
    Cancer Res; 1979 Aug; 39(8):3089-94. PubMed ID: 455293
    [No Abstract]   [Full Text] [Related]  

  • 26. Design, synthesis and activity of bisubstrate, transition-state analogues and competitive inhibitors of aspartate transcarbamylase.
    Grison C; Coutrot P; Comoy C; Balas L; Joliez S; Lavecchia G; Oliger P; Penverne B; Serre V; Hervé G
    Eur J Med Chem; 2004 Apr; 39(4):333-44. PubMed ID: 15072842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetic parameters of aspartate transcarbamylase in human normal and tumoral cell lines.
    Baillon J; Guichard M; Malaise EP; Hervé G
    Cancer Res; 1983 May; 43(5):2277-82. PubMed ID: 6831451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mass spectrometric technique for the determination of N-phosphonoacetyl-L-aspartic acid in serum.
    Roboz J; Suzuki R; Rose E
    J Chromatogr; 1980 Feb; 181(2):195-205. PubMed ID: 7372753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A facile enzymatic technique for the estimation of nanomolar concentrations of N-phosphonacetyl-L-aspartic acid in plasma.
    Kensler TW; Jayaram HN; Cooney DA
    J Biochem Biophys Methods; 1980; 2(1):29-35. PubMed ID: 6999068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid.
    Loh E; Kufe DW
    Cancer Res; 1981 Sep; 41(9 Pt 1):3419-23. PubMed ID: 7260907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers.
    Sharma A; Straubinger NL; Straubinger RM
    Pharm Res; 1993 Oct; 10(10):1434-41. PubMed ID: 8272404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficient synthesis of fluorothiosparfosic acid analogues with potential antitumoral activity.
    Pfund E; Lequeux T; Masson S; Vazeux M; Cordi A; Pierre A; Serre V; Hervé G
    Bioorg Med Chem; 2005 Aug; 13(16):4921-8. PubMed ID: 15975800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-(phosphonacetyl)-L-aspartate, a potent transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of mammalian cells in culture.
    Swyryd EA; Seaver SS; Stark GR
    J Biol Chem; 1974 Nov; 249(21):6945-50. PubMed ID: 4371054
    [No Abstract]   [Full Text] [Related]  

  • 34. Inhibition by N-(phosphonacetyl)-L-aspartate of aspartate transcarbamylase activity and drug-induced cell proliferation in mice.
    Yoshida T; Stark GR; Hoogenraad J
    J Biol Chem; 1974 Nov; 249(21):6951-5. PubMed ID: 4418148
    [No Abstract]   [Full Text] [Related]  

  • 35. Carrot cells detoxify N-phosphonoacetyl-L-aspartate by esterification.
    Cole SC; Yon RJ
    Biochem J; 1988 Nov; 255(3):813-6. PubMed ID: 3214426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aspartate transcarbamylase from Leishmania donovani. A discrete, nonregulatory enzyme as a potential chemotherapeutic site.
    Mukherjee T; Ray M; Bhaduri A
    J Biol Chem; 1988 Jan; 263(2):708-13. PubMed ID: 2891701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adenylosuccinate synthetase from Dictyostelium discoideum: effects of hadacidin analogs and binding of [14C]hadacidin.
    Jahngen EG; Rossomando EF
    Arch Biochem Biophys; 1984 Feb; 229(1):145-54. PubMed ID: 6703692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pyrimidine pathways enzymes in human tumors of brain and associated tissues: potentialities for the therapeutic use of N-(phosphonacetyl-L-aspartate and 1-beta-D-arabinofuranosylcytosine.
    Madani S; Baillon J; Fries J; Belhadj O; Bettaieb A; Ben Hamida M; Hervé G
    Eur J Cancer Clin Oncol; 1987 Oct; 23(10):1485-90. PubMed ID: 2824206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DON, CONV and DONV-II. Inhibition of L-'asparagine synthetase in vivo.
    Rosenbluth RJ; Cooney DA; Jayaram HN; Milman HA; Homan ER
    Biochem Pharmacol; 1976 Aug; 25(16):1851-8. PubMed ID: 9091
    [No Abstract]   [Full Text] [Related]  

  • 40. Aminomalonic acid and its congeners as potential in vivo inhibitors of L-asparagine synthetase.
    Milman HA; Muth R; Cooney DA
    Enzyme; 1979; 24(1):36-47. PubMed ID: 35346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.